Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : EU drug regulator finds link between AstraZeneca vaccine and blood clots

04/07/2021 | 10:08am EDT
FILE PHOTO: Vial labelled

(Reuters) - Europe's drug regulator on Wednesday found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all available evidence.

"One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin," the European Medicines Agency (EMA) said.

The findings come as a major hurdle in the global fight against the pandemic and a shift in the stance of the regulator, which had last week backed the vaccine and said there was no increased risk of blood clots in general from the shot.

It is also a blow to AstraZeneca, which was a frontrunner in the race for making an effective vaccine against COVID-19 ever since it began working with the University of Oxford.

The EMA's safety committee, which was assessing the vaccine, has requested for more studies and changes to the current ones to get more information.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

© Reuters 2021
All news about ASTRAZENECA PLC
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
12:08pLONDON STOCK EXCHANGE : FTSE 100 ends lower as miners track lower metal prices; ..
10:25aASTRAZENECA  : Argus Research Downgrades AstraZeneca to Hold From Buy
09:35aASTRAZENECA  : Ireland set to restrict use of AstraZeneca vaccine -RTE
09:33aAustralia Expects Big Delays to Vaccine Rollout
09:02aBulgarian PM reveals price for EU's new vaccine contract with Pfizer
08:54aASTRAZENECA  : Indian panel gives emergency approval for Russia's Sputnik V vacc..
08:35aASTRAZENECA  : Brazil, Mexico, Philippines among those due to get Pfizer shots f..
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
07:26aEUROPE ECONOMICS : Action Economics on The UK Week Ahead; COVID-19 Vaccine Rollo..
More news
Financials (USD)
Sales 2021 30 893 M - -
Net income 2021 4 586 M - -
Net Debt 2021 14 367 M - -
P/E ratio 2021 27,7x
Yield 2021 2,86%
Capitalization 131 B 131 B -
EV / Sales 2021 4,71x
EV / Sales 2022 4,06x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 130,05 $
Last Close Price 99,88 $
Spread / Highest target 66,2%
Spread / Average Target 30,2%
Spread / Lowest Target -5,71%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.51%131 272
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164